Related Experiment Video
Updated: Apr 25, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.3K
DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello1, Liberata Sportiello, Concetta Rafaniello
1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Department of Endocrinology , Barcelona , Spain.
Expert Opinion on Drug Safety
|August 30, 2014
Summary
Dipeptidyl peptidase-4 inhibitors (DPP-4i) offer effective type 2 diabetes management with varying pharmacokinetics but similar safety profiles. They are beneficial for specific patient groups, though cardiovascular outcomes require further investigation.
Area of Science:
- Pharmacology
- Endocrinology
- Internal Medicine
Background:
- Incretin-based therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4i), are increasingly utilized for type 2 diabetes (T2D) management.
- Specific DPP-4i agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin.
Purpose of the Study:
- To analyze the pharmacological characteristics of DPP-4 inhibitors.
- To evaluate the clinical implications and therapeutic role of DPP-4 inhibitors in T2D management.
Main Methods:
- An extensive literature search was conducted.
- Pharmacological properties and clinical data of DPP-4 inhibitors were analyzed.
Main Results:
- DPP-4 inhibitors exhibit distinct pharmacokinetic profiles, chemical structures, enzyme inhibition selectivity, and potency.
- Observed disparities exist in effects on HbA1c, GLP-1, glucagon levels, and glucose variability.
- Indirect comparisons suggest similar safety and efficacy across all DPP-4 inhibitors.
Conclusions:
- DPP-4 inhibitors are advantageous for overweight/obese and elderly T2D patients due to minimal weight impact and low hypoglycemia risk.
- These agents can be safely co-administered with insulin.
- Cardiovascular outcomes associated with DPP-4 inhibitors remain debated, with ongoing studies to clarify their long-term impact.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
986
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
986
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
945
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
945
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:03Pharmacodynamic Responses: Different Types
156
Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...
156